Schering-Plough has received marketing approval for Remeron/Reflex (mirtazapine) 15mg tablets, for the treatment of major depressive disorder. The product was developed jointly with Meiji Seika Kabushiki Kaisha. Schering-Plough and Meiji Seika would market the product under the trade names, REMERON and Reflex, respectively.
Thomas Koestler, President and Executive Vice President of Schering-Plough Research Institute, said: Remeron came to us from the Organon research laboratories, and we are pleased that this new treatment option will now be available in Japan to help meet the needs of physicians and their patients suffering from depression.
This approval is the eighth new product we have brought to the Japanese market since 2007 and represents important progress in extending our presence in Japan, a critical part of our geographic expansion, he added.